Author: Dr. Laura BonebrakeWhat we know about risks and outcomes Intrahepatic cholestasis of pregnancy (ICP) is classically known as a disorder that first occurs in the second or third trimesters of pregnancy.1 At ICP Care, we have had members diagnosed much earlier...
It’s the burning question everyone with Intrahepatic Cholestasis of Pregnancy wants the answer to: can my ICP cause lasting harm to me or my baby after my pregnancy is over? It’s unsatisfying to know we don’t have great answers. The studies so far have been few and often conflicting. We do have some answers, though, and it’s mostly good news.
New Evidence from two new studies have been published that support the benefits of Ursodiol to treat Intrahepatic Cholestasis of Pregnancy.
Overall, the study was well-designed. However, there was one important issue with ursodeoxycholic acid that may have profoundly impacted results.
In February of 2019, a groundbreaking study was published regarding Intrahepatic Cholestasis of Pregnancy (ICP), which found that under modern management practices the risk of stillbirth is not higher until bile acids reach 100 μmol/L. The study was a fantastic...
Have you recently been diagnosed with ICP?
Would you like your personal experience, test results and medical treatment with this rare disease to further the advancement of science? Find out how your diagnosis can help through our Patient Registry.